Drug Type Small molecule drug |
Synonyms AR 1001, AR-1001, AR1001 |
Target |
Action inhibitors |
Mechanism PDE5A inhibitors(Phosphodiesterase 5A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H11N |
InChIKeyRIWRFSMVIUAEBX-UHFFFAOYSA-N |
CAS Registry103-67-3 |
Start Date23 Dec 2022 |
Sponsor / Collaborator |
Start Date01 Apr 2019 |
Sponsor / Collaborator |
Start Date- |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 3 | United States | 23 Dec 2022 | |
Alzheimer Disease | Phase 3 | China | 23 Dec 2022 | |
Alzheimer Disease | Phase 3 | Czechia | 23 Dec 2022 | |
Alzheimer Disease | Phase 3 | Denmark | 23 Dec 2022 | |
Alzheimer Disease | Phase 3 | France | 23 Dec 2022 | |
Alzheimer Disease | Phase 3 | Germany | 23 Dec 2022 | |
Alzheimer Disease | Phase 3 | Italy | 23 Dec 2022 | |
Alzheimer Disease | Phase 3 | Netherlands | 23 Dec 2022 | |
Alzheimer Disease | Phase 3 | Poland | 23 Dec 2022 | |
Alzheimer Disease | Phase 3 | Spain | 23 Dec 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 210 | ehihqxdoal(qyutedixcw) = ovrmmgvjhg cefstidgyf (uffpdschfu ) | Positive | 04 Nov 2021 | |||
aiinbplecs(gzjatalgrc) = islakefgyg ozpuivznvm (bdlvmmucdy ) View more |